Overview: TDT Immunohistochemistry TestIntroduction: The TDT Immunohistochemistry Test detects terminal deoxynucleotidyl transferase (TDT) to diagnose acute lymphoblastic leukemia (ALL), causing fatigue or fever. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected ALL.
Other Names: TDT IHC Assay, ALL IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: TDT testing began in the 1970s with leukemia research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects TDT to diagnose acute lymphoblastic leukemia, guides treatment, and evaluates patients with fatigue or fever.
Test Parameters: 1. Terminal Deoxynucleotidyl Transferase
Pretest Condition: No fasting required. Collect tissue via bone marrow biopsy or lymph node biopsy. Report history of fatigue, fever, or bleeding.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, fever, bruising, or family history of leukemia. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, leukemia implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect TDT in bone marrow or lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for ALL diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive TDT staining confirms ALL, guiding chemotherapy or transplant. Negative staining may require further leukemia marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD10 IHC, flow cytometry, or bone marrow biopsy to confirm ALL diagnosis.
Test Limitations: Not specific to ALL; other leukemias may express TDT. Clinical correlation is needed.
References: WHO Hematopathology Guidelines, 2023; Blood, Arber DA, 2022.
